ABVC BioPharma (ABVC) Q3 2024 earnings summary

Executive summary

• Revenue for Q3 2024 was $389,276, up 2,351% year-over-year, driven by licensing deals and R&D services in CNS and oncology.

• Net loss for Q3 2024 was $134,272, a 96% improvement from $3,369,080 in Q3 2023, reflecting disciplined cost management and higher revenues.

• Achieved first operational profit in Q3 2024, marking a 102% improvement over Q3 2023.

• For the nine months ended September 30, 2024, revenue rose 238% to $507,623, and net loss narrowed by 29% to $5,387,980.

• Secured global licensing agreements with potential income up to $292 million and received $496,000 in milestone payments for the nine months ended September 30, 2024.

Financial highlights

• Q3 2024 gross profit was $388,980, compared to a loss of $13,730 in Q3 2023.

• Operating expenses for Q3 2024 decreased 84% year-over-year to $339,033, mainly from reduced SG&A and R&D costs.

• Cash and cash equivalents as of September 30, 2024, were $137,344, up from $60,155 at year-end 2023.

• Net cash used in operating activities for the nine months ended September 30, 2024, was $1,315,534, a significant improvement from $3,756,385 in the prior year period.

• Shareholders' equity stood at $7.98 million as of September 30, 2024.

Outlook and guidance

• Management plans to improve cash flows by collecting licensing payments, raising capital, controlling expenses, and reducing debt.

• Anticipates further revenue growth through strategic collaborations, clinical developments, and new market entries.

• Expects global licensing agreements to deliver recurring income and support long-term growth.

• Preparing for FDA End-of-Phase 2 meeting for ABV-1504 and interim ADHD trial report by Q4 2024.